News
10-15-2013, 12:15 AM
Merck, known as MSD outside the United States and Canada, (NYSE: MRK) and Endocyte, Inc. (NASDAQ: ECYT) today announced the online publication of results from the randomized Phase II PRECEDENT trial for vintafolide (MK-8109/EC145), an investigational folate small molecule drug conjugate (SMDC), in the Journal of Clinical Oncology (JCO), the official journal of the American Society of Clinical Oncology.
More... (http://www.news-medical.net/news/20131015/Results-announced-for-Phase-II-PRECEDENT-trial-of-vintafolide-in-treatment-of-platinum-resistant-ovarian-cancer.aspx)
More... (http://www.news-medical.net/news/20131015/Results-announced-for-Phase-II-PRECEDENT-trial-of-vintafolide-in-treatment-of-platinum-resistant-ovarian-cancer.aspx)